2026 Buyer's Guide
Weight Loss Injections (2026): Every FDA-Approved Option
Five FDA-approved injectable medications can produce meaningful weight loss in 2026. Three (Wegovy, Zepbound, Saxenda) are FDA-approved specifically for chronic weight management. Two (Ozempic, Mounjaro) are FDA-approved for type 2 diabetes but commonly prescribed off-label for weight loss. Below: side-by-side comparison, how they work, what they cost, and where to get them.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
About this page
Every drug listed below is FDA-approved with a published label on DailyMed (NIH). Mechanism, indication, administration route, dosing, and approval-date data are pulled from our primary-source-verified drug database. Cost data was verified live in July 2026 from manufacturer self-pay portals (NovoCare, LillyDirect), retailer programs (Costco Member Value Pricing, Sam's Club Plus, Amazon Pharmacy), and GoodRx. We do not paraphrase indication language.
What are weight loss injections?
All five FDA-approved weight loss injections currently on the US market are GLP-1 receptor agonists (one is also a GIP/GLP-1 dual agonist). They are self-administered subcutaneous injections — a small needle into the fat layer of the abdomen, thigh, or back of the upper arm — and they reduce appetite via the GLP-1 signaling pathway plus slow gastric emptying. Three are FDA-approved for chronic weight management; two are FDA-approved for type 2 diabetes and prescribed off-label for weight loss when the weight-loss-indicated drugs are unavailable, denied by insurance, or contraindicated. The class history started with Byetta (exenatide) in 2005 for type 2 diabetes; Saxenda was the first weight-management indication in December 2014; Wegovy, Zepbound, and Foundayo followed.
For the deeper biology of GLP-1 — what the hormone is, how the receptor works, and the four physiologic actions (insulin secretion, glucagon suppression, gastric emptying, central appetite suppression) — see our GLP-1 complete guide. For oral weight loss medications (the Wegovy pill, Foundayo, Qsymia, Contrave, Xenical), see our FDA-approved weight loss medications hub (which compares pills vs injections side-by-side).
Every FDA-approved weight loss injection, compared
All five injections side-by-side. Pivotal trial efficacy cited from the canonical phase 3 publication for each drug; full PMID citations live in our bariatric vs GLP-1 decision guide.
| Brand | Generic | Indication | Guide |
|---|---|---|---|
| Wegovy | Semaglutide 2.4 mg | Weight management; CV risk reduction | Wegovy → |
| Zepbound | Tirzepatide | Weight management; OSA in obesity | Zepbound → |
| Saxenda | Liraglutide 3 mg | Chronic weight management | DailyMed → |
| Ozempic | Semaglutide (lower-dose) | Type 2 diabetes (off-label for weight loss) | Ozempic → |
| Mounjaro | Tirzepatide | Type 2 diabetes (off-label for weight loss) | Mounjaro → |
What weight loss injections cost in 2026
Brand-name injection list prices range widely depending on channel. Verified live in May 2026 from manufacturer + retailer primary sources:
Wegovy (semaglutide)
- NovoCare self-pay: $349/month (standard pen, all doses 0.25–2.4 mg; $199 for a new patient's first two months of 0.25/0.5 mg)
- NovoCare HD pen 7.2 mg: $399/month
- Wegovy oral pill: $149/month (1.5 mg; $199 for 4 mg, $299 for 9 and 25 mg)
- Costco Member Value Pricing: $349/month (1–2.4 mg; $199 for 0.25/0.5 mg, 2 fills)
- Sam's Club: $499/month via copay program
- Insured, using the copay savings card: from $25/month
Zepbound (tirzepatide)
- LillyDirect vials self-pay (effective Dec 1, 2025): $299 / $399 / $449 by strength
- LillyDirect KwikPen self-pay: $299–$699 by strength
- Sam's Club KwikPen: $299/$399/$499/$699
- GoodRx coupon path: $299/month (manufacturer-funded)
Saxenda (liraglutide)
- Brand list: ~$1,300/month
- Generic liraglutide (Teva, launched Aug 28 2025): pricing varies by pharmacy
- Manufacturer copay savings card: as little as $25/month for commercially insured
Ozempic (off-label) + Mounjaro (off-label)
- Ozempic NovoCare new patient: $199/mo for first 2 months; $349 standard
- Ozempic pill (NovoCare self-pay): $149/month at 1.5 mg ($199 at 4 mg, $299 at 9 mg)
- Mounjaro LillyDirect self-pay: from $499/month at every dose; copay savings card for commercial
- Off-label use is rarely insurance-covered for weight loss when the patient does not have type 2 diabetes
For the live channel-by-channel pricing index across every channel + compounded options ($99–$400/mo), see our GLP-1 pricing index. Brand and compounded GLP-1s are generally HSA/FSA-eligible with a prescription per IRS Publication 502.
How to get a weight loss injection (telehealth, retail, insurance)
Three primary channels:
- Insurance + traditional prescriber. Your PCP or an obesity-medicine specialist writes the prescription, your pharmacy fills it, your insurance applies the prior-authorization criteria. See our Cigna PA guide and Aetna PA guide for verbatim payer policy. The Cigna 11-condition comorbidity list, the Aetna 6-month behavioral-program requirement, and the CVS Caremark July 2025 Wegovy- preferred swap are the three things most prescribers under-document.
- GLP-1 telehealth providers. Online clinic + 503A pharmacy partnership. Cash-pay compounded semaglutide / tirzepatide typically $99–$400/ month. See our best semaglutide providers and best tirzepatide providers for ranked options. Note: the FDA's enforcement-discretion grace period for compounded semaglutide ended February 2025 — the regulatory landscape is unsettled.
- Direct-to-consumer manufacturer pharmacies. NovoCare (Wegovy/Ozempic), LillyDirect (Zepbound/ Mounjaro/Foundayo), Costco Member Value Pricing, Sam's Club Plus, Amazon Pharmacy. Cash-pay only — not eligible for insurance.
Once you have the medication, follow the FDA-label injection technique. See our step-by-step injection technique guide for every common pen and vial format, including the three FDA-approved injection sites (abdomen, thigh, back of upper arm), needle gauge, depth, angle, and the site-rotation schedule that minimizes lipohypertrophy.
Compare vetted GLP-1 telehealth providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
No insurance needed · HSA/FSA eligible · vetted by our editors
Ro
FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Starting price: $149/mo (+ required membership)
Get started →Read review Ro →Collective
The lowest flat medication price if you can absorb an annual membership fee
Starting price: $59/mo (+ required membership)
Get started →Read review Collective →CoreAge Rx
Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Starting price: $79/mo (“starting at” price)
Get started →Read review CoreAge Rx →Embody
Low flat-rate compounded GLP-1 pricing at every dose
Starting price: $79/mo (sale price)
Get started →Read review Embody →Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Starting price: $129/mo (starting dose)
Get started →Read review Gala →Found
Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
Starting price: $169/mo (12-month plan rate)
Get started →Read review Found →| Provider | Starting price | |
|---|---|---|
7.7Ro | $149/mo (+ required membership) | Get started → |
8.3Collective | $59/mo (+ required membership) | Get started → |
8.3CoreAge Rx | $79/mo (“starting at” price) | Get started → |
7.8Embody | $79/mo (sale price) | Get started → |
8.2Gala | $129/mo (starting dose) | Get started → |
8.3Found | $169/mo (12-month plan rate) | Get started → |
Frequently Asked Questions
References
- 1.U.S. Food and Drug Administration / manufacturer label. Wegovy — FDA Prescribing Information (indication, dosing schedule, and boxed-warning language quoted verbatim from the current label). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 2.U.S. Food and Drug Administration / manufacturer label. Zepbound — FDA Prescribing Information (indication, dosing schedule, and boxed-warning language quoted verbatim from the current label). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 3.U.S. Food and Drug Administration / manufacturer label. Ozempic — FDA Prescribing Information (indication, dosing schedule, and boxed-warning language quoted verbatim from the current label). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- 4.U.S. Food and Drug Administration / manufacturer label. Mounjaro — FDA Prescribing Information (indication, dosing schedule, and boxed-warning language quoted verbatim from the current label). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- 5.U.S. Food and Drug Administration / Novo Nordisk label. Saxenda (liraglutide 3 mg) — FDA Prescribing Information (dosing ladder, indication, and boxed-warning language quoted verbatim from the current label). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- 6.Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — ~20.9% mean body-weight reduction at 72 weeks (15 mg). New England Journal of Medicine. 2022. PMID: 35658024.
- 7.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — ~14.9% mean body-weight reduction at 68 weeks (2.4 mg). New England Journal of Medicine. 2021. PMID: 33567185.
- 8.Garvey WT, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — head-to-head superiority of tirzepatide over semaglutide. New England Journal of Medicine. 2025. PMID: 40334173.
- 9.Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes) — ~5-8% mean body-weight reduction at 56 weeks. New England Journal of Medicine. 2015. PMID: 26132939.
- 10.Novo Nordisk. NovoCare self-pay pricing for Wegovy and Ozempic — cash-pay pen pricing verified live July 2026. novocare.com. 2026. https://www.novocare.com/
- 11.Eli Lilly and Company. LillyDirect self-pay pricing for Zepbound single-dose vials — cash-pay vial pricing by strength verified live July 2026. lilly.com/lillydirect. 2026. https://lillydirect.lilly.com/